The PEGylated human recombinant FGF21 pegbelfermin (ARX-618) has recently demonstrated suboptimal efficacy in compensated cirrhosis due to NASH in the FALCON 2 trial, resulting in pending discontinuation and/or possible repurposing for other indications [76]. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatohepatitis.